Overview

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Chugai Pharmaceutical
Collaborator:
Hoffmann-La Roche
Treatments:
Sorafenib